
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio Inc is positioned positively due to its ongoing development of immune cell modulating antibodies, including two key assets—rosnilimab and ANB032—in clinical-stage trials targeting significant autoimmune and inflammatory diseases. The promising efficacy data reported for rosnilimab in mitigating gastrointestinal symptoms indicates a favorable risk/reward profile, especially in relation to upcoming data for its use in ulcerative colitis and the protection provided by ongoing Jemperli royalties. Furthermore, the company's valuation appears robust with updated projections for royalties contributing to an increased price target, reflecting positive expectations for its future financial health.
Bears say
AnaptysBio Inc faces significant challenges that may adversely impact its stock performance, primarily due to the inherent risks associated with its clinical-stage development programs. Concerns surrounding potential safety signals, suboptimal efficacy in clinical trials, and increasing commercial competition could hinder the approval and market success of key product candidates like rosnilimab and Jemperli. Furthermore, if sales projections for these products fail to materialize due to intense market competition or reimbursement issues, the company's financial outlook may be further compromised, causing broader implications for investor confidence.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares